PRKAG3抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using PRKAG3 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum tissues using PRKAG3 mouse mAb with DAB staining.    

  
  

The PRKAG3 antibody is a tool used to detect the PRKAG3 protein, a regulatory subunit of AMP-activated protein kinase (AMPK), which plays a central role in cellular energy homeostasis. AMPK is a heterotrimeric enzyme composed of α (catalytic), β, and γ (regulatory) subunits. PRKAG3 (protein kinase AMP-activated gamma 3 non-catalytic subunit) is specifically encoded by the PRKAG3 gene and is predominantly expressed in skeletal muscle. This subunit influences AMPK’s sensitivity to AMP/ATP levels, modulating its activity during metabolic stress. PRKAG3 has been linked to glycogen metabolism, muscle fiber composition, and energy balance regulation.

Mutations in PRKAG3 are associated with metabolic disorders. For instance, specific variants cause glycogen storage disease and cardiac hypertrophy in animal models, highlighting its role in glucose utilization and muscle function. In humans, PRKAG3 polymorphisms may affect exercise adaptation, insulin sensitivity, and obesity-related traits. Researchers use PRKAG3 antibodies in techniques like Western blotting, immunohistochemistry, and ELISA to study its expression, localization, and interactions in tissues. These studies help elucidate mechanisms underlying metabolic diseases, muscle physiology, and potential therapeutic targets. The antibody’s specificity and reliability are critical for distinguishing PRKAG3 from other gamma subunits (e.g., PRKAG1. PRKAG2) in experimental settings. Its application spans basic research, clinical diagnostics, and drug development, particularly in conditions like diabetes, obesity, and myopathies.